Edgestream Partners’s Akero Therapeutics AKRO Stock Holding History

Edgestream Partners’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,947	Closed	-$281K	–	835
2025 Q1	$281K	Buy	+6,947	New	+$294K	0.01%	772

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edgestream Partners's AKRO Position: Q2 2025 in Review

Edgestream Partners sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 6,947 shares — an estimated $281K sold.

Edgestream Partners first reported a position in AKRO in Q1 2025 and held it in 1 quarter. The position peaked at $281K in Q1 2025. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

Edgestream Partners reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
Edgestream Partners sold 6,947 Akero Therapeutics shares in Q2 2025, an estimated $281K.
Edgestream Partners first reported a position in Akero Therapeutics in Q1 2025 and held it in 1 quarter.
Edgestream Partners's Akero Therapeutics position peaked at $281K in Q1 2025.
257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Edgestream Partners's 13F filing for Q2 2025, filed 13 Aug 2025.